Evidence map›Paper›PMID 40460269›Full record

ArticleActa orthopaedica2025

Hospital-related healthcare expenditure of impending versus completed pathological femur fractures: a propensity score matched study of 265 patients.

Tom M De Groot, Michelle R Shimizu, David Shin, Olivier Q Groot, Stein J Janssen, Kevin A Raskin, Eric T Newman, Marco L Ferrone, Santiago A Lozano-Calderon, Joseph H Schwab and 1 more

Abstract readComparative Study
In one paragraph

Article in Acta orthopaedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tom M De GrootDepartment of Orthopedics, Massachusetts General Hospital, Boston, MA, USA; Department of Orthopedics, University Medical Center Groningen, Groningen, The Netherlands. t.m.de.groot@umcg.nl.
Michelle R ShimizuDepartment of Orthopedics, Massachusetts General Hospital, Boston, MA, USA.
David ShinDepartment of Orthopedics, Massachusetts General Hospital, Boston, MA, USA.
Olivier Q GrootDepartment of Orthopedics, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-5091-3110
Stein J JanssenDepartment of Orthopaedic Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0003-3939-7765
Kevin A RaskinDepartment of Orthopedics, Massachusetts General Hospital, Boston, MA, USA.
Eric T NewmanDepartment of Orthopedics, Massachusetts General Hospital, Boston, MA, USA.
Marco L FerroneDepartment of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Santiago A Lozano-CalderonDepartment of Orthopedics, Massachusetts General Hospital, Boston, MA, USA.
Joseph H Schwab *Department of Orthopedic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Paul C Jutte *Department of Orthopedics, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-6022-2807

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe prevalence of metastatic bone disease as well as the accompanying societal costs are expected to increase due to advances in cancer treatment. While the literature suggests that there is economic value in prophylactic stabilization compared with the fixation of completed pathological fractures in long bone metastases, studies are limited by their small sample sizes and insufficient correction for potential confounders. We aimed to evaluate whether prophylactic treatment of an impending femur fracture was associated with lower healthcare costs compared with completed pathologic fractures. We further aimed to compare prophylactic surgical treatment with completed pathological fractures in terms of postoperative complications, discharge disposition, and postoperative length of stay.

methodsThis is a retrospective cohort study with propensity score matching (PSM). We included clinical and financial data for 265 patients who received surgery for impending (n = 161) or completed (n = 104) femoral fractures of metastatic lesions, from 2 affiliated urban tertiary care centers between 2016 and 2020 in the United States. After PSM on 13 variables, including demographics and clinical characteristics, 100 impending fractures were matched with 100 completed fractures. The primary outcome was healthcare costs per episode of care, defined as the total cost from admission to 30 days after discharge.

resultsWe found no difference in total cost of care between patients undergoing prophylactic surgical treatment and patients who underwent surgical treatment for a completed pathological fracture (median difference 44 cost-units [CU], 95% confidence interval [CI] -294 to 262). No differences were seen when dividing total cost into cost during hospital admission (median difference -25 CUs, CI -152 to 159) and 30 days following discharge (median difference 31 CUs, CI -74 to 88). Patients with completed pathologic fractures were more often discharged to rehabilitation facilities (57/100, vs 30/100, P < 0.01).

conclusionIn contrast to earlier findings, we showed no difference in treatment costs between surgical management of impending and completed pathological fractures of femur metastases after adjusting for confounding factors. However, patients with completed pathological fractures were significantly more likely to require discharge to rehabilitation facilities, highlighting potential out-of-hospital costs related to extended rehabilitation, reduced mobility, and loss of independence.

Indexed as

Bone NeoplasmsFemoral FracturesFractures, SpontaneousHealth ExpendituresAdultAgedFemaleHumansLength of StayMaleMiddle AgedPropensity ScoreRetrospective Studies

Identifiers

PMID40460269
PMCPMC12118376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.